^
Association details:
| Biomarker: | HER-2 amplification |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + pilaralisib (SAR245408) (PI3K inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors
Excerpt:
We treated a panel of trastuzumab-resistant HER2 gene-amplified human breast cancer cells with the pan-PI3K inhibitor XL147...Treatment with XL147 + trastuzumab but not CI-1040 + trastuzumab inhibited monolayer (Fig. 1A) and 3D growth (Fig. 1B) in all resistant lines.
DOI:
10.1158/0008-5472.CAN-12-2440
